220 related articles for article (PubMed ID: 25063315)
1. Analysis of clinical characteristics and differential diagnosis of the lung biopsy specimens in 99 adenocarcinoma cases and 111 squamous cell carcinoma cases: utility of an immunohistochemical panel containing CK5/6, CK34βE12, p63, CK7 and TTF-1.
Xu XY; Yang GY; Yang JH; Li J
Pathol Res Pract; 2014 Oct; 210(10):680-5. PubMed ID: 25063315
[TBL] [Abstract][Full Text] [Related]
2. Best immunohistochemical panel in distinguishing adenocarcinoma from squamous cell carcinoma of lung: tissue microarray assay in resected lung cancer specimens.
Kim MJ; Shin HC; Shin KC; Ro JY
Ann Diagn Pathol; 2013 Feb; 17(1):85-90. PubMed ID: 23040737
[TBL] [Abstract][Full Text] [Related]
3. Value of P63 and CK5/6 in distinguishing squamous cell carcinoma from adenocarcinoma in lung fine-needle aspiration specimens.
Khayyata S; Yun S; Pasha T; Jian B; McGrath C; Yu G; Gupta P; Baloch Z
Diagn Cytopathol; 2009 Mar; 37(3):178-83. PubMed ID: 19170169
[TBL] [Abstract][Full Text] [Related]
4. [Expression of TTF-1, NapsinA, P63, CK5/6 in Lung Cancer and Its Diagnostic Values for Histological Classification].
Yu H; Li L; Liu D; Li WM
Sichuan Da Xue Xue Bao Yi Xue Ban; 2017 May; 48(3):336-341. PubMed ID: 28616902
[TBL] [Abstract][Full Text] [Related]
5. Subclassification of non-small cell lung carcinomas lacking morphologic differentiation on biopsy specimens: Utility of an immunohistochemical panel containing TTF-1, napsin A, p63, and CK5/6.
Mukhopadhyay S; Katzenstein AL
Am J Surg Pathol; 2011 Jan; 35(1):15-25. PubMed ID: 21164283
[TBL] [Abstract][Full Text] [Related]
6. Utility of 10 immunohistochemical markers including novel markers (desmocollin-3, glypican 3, S100A2, S100A7, and Sox-2) for differential diagnosis of squamous cell carcinoma from adenocarcinoma of the Lung.
Tsuta K; Tanabe Y; Yoshida A; Takahashi F; Maeshima AM; Asamura H; Tsuda H
J Thorac Oncol; 2011 Jul; 6(7):1190-9. PubMed ID: 21623236
[TBL] [Abstract][Full Text] [Related]
7. The diagnostic value of TTF-1, CK 5/6, and p63 immunostaining in classification of lung carcinomas.
Kargi A; Gurel D; Tuna B
Appl Immunohistochem Mol Morphol; 2007 Dec; 15(4):415-20. PubMed ID: 18091384
[TBL] [Abstract][Full Text] [Related]
8. Utility of WT-1, p63, MOC31, mesothelin, and cytokeratin (K903 and CK5/6) immunostains in differentiating adenocarcinoma, squamous cell carcinoma, and malignant mesothelioma in effusions.
Pu RT; Pang Y; Michael CW
Diagn Cytopathol; 2008 Jan; 36(1):20-5. PubMed ID: 18064689
[TBL] [Abstract][Full Text] [Related]
9. The Value of Cytokeratin 5/6, p63 and Thyroid Transcription Factor-1 in Adenocarcinoma, Squamous Cell Carcinoma and Non-Small-Cell Lung Cancer of the Lung.
Argon A; Nart D; Veral A
Turk Patoloji Derg; 2015; 31(2):81-8. PubMed ID: 25944390
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of napsin A, cytokeratin 5/6, p63, and thyroid transcription factor 1 in adenocarcinoma versus squamous cell carcinoma of the lung.
Whithaus K; Fukuoka J; Prihoda TJ; Jagirdar J
Arch Pathol Lab Med; 2012 Feb; 136(2):155-62. PubMed ID: 22288962
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical algorithm for differentiation of lung adenocarcinoma and squamous cell carcinoma based on large series of whole-tissue sections with validation in small specimens.
Rekhtman N; Ang DC; Sima CS; Travis WD; Moreira AL
Mod Pathol; 2011 Oct; 24(10):1348-59. PubMed ID: 21623384
[TBL] [Abstract][Full Text] [Related]
12. Expression of p63, keratin 5/6, keratin 7, and surfactant-A in non-small cell lung carcinomas.
Camilo R; Capelozzi VL; Siqueira SA; Del Carlo Bernardi F
Hum Pathol; 2006 May; 37(5):542-6. PubMed ID: 16647951
[TBL] [Abstract][Full Text] [Related]
13. Differential expression of cytokeratins 7 and 20 and thyroid transcription factor-1 in bronchioloalveolar carcinoma: an immunohistochemical study in fine-needle aspiration biopsy specimens.
Simsir A; Wei XJ; Yee H; Moreira A; Cangiarella J
Am J Clin Pathol; 2004 Mar; 121(3):350-7. PubMed ID: 15023039
[TBL] [Abstract][Full Text] [Related]
14. Large-scale comparative analyses of immunomarkers for diagnostic subtyping of non-small-cell lung cancer biopsies.
Warth A; Muley T; Herpel E; Meister M; Herth FJ; Schirmacher P; Weichert W; Hoffmann H; Schnabel PA
Histopathology; 2012 Dec; 61(6):1017-25. PubMed ID: 22882703
[TBL] [Abstract][Full Text] [Related]
15. Optimal immunohistochemical markers for distinguishing lung adenocarcinomas from squamous cell carcinomas in small tumor samples.
Terry J; Leung S; Laskin J; Leslie KO; Gown AM; Ionescu DN
Am J Surg Pathol; 2010 Dec; 34(12):1805-11. PubMed ID: 21107086
[TBL] [Abstract][Full Text] [Related]
16. The utility of TTF-1, napsin A, CK5 and p63 staining in the sub-classification of non-small cell carcinoma of the lung.
van Zyl A; Schubert PT; Koegelenberg CFN
Cytopathology; 2019 Nov; 30(6):586-591. PubMed ID: 31206846
[TBL] [Abstract][Full Text] [Related]
17. The role of the cytopathologist in subtyping and epidermal growth factor receptor testing in non-small cell lung cancer: An institutional experience.
Sekar A; Gupta N; Rajwanshi A; Chaturvedi R; Singh N; Lal A
Cytopathology; 2017 Oct; 28(5):371-377. PubMed ID: 28730709
[TBL] [Abstract][Full Text] [Related]
18. Role of TTF-1, CK20, and CK7 immunohistochemistry for diagnosis of primary and secondary lung adenocarcinoma.
Su YC; Hsu YC; Chai CY
Kaohsiung J Med Sci; 2006 Jan; 22(1):14-9. PubMed ID: 16570563
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of napsin A, TTF-1, p63, p40, and CK5/6 immunohistochemical stains in pulmonary neuroendocrine tumors.
Zhang C; Schmidt LA; Hatanaka K; Thomas D; Lagstein A; Myers JL
Am J Clin Pathol; 2014 Sep; 142(3):320-4. PubMed ID: 25125621
[TBL] [Abstract][Full Text] [Related]
20. Tissue-sparing application of the newly proposed IASLC/ATS/ERS classification of adenocarcinoma of the lung shows practical diagnostic and prognostic impact.
Sterlacci W; Savic S; Schmid T; Oberaigner W; Auberger J; Fiegl M; Tzankov A
Am J Clin Pathol; 2012 Jun; 137(6):946-56. PubMed ID: 22586054
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
